2nd Quarter 2023 Results

2nd Quarter 2023 Sales

$25.5B | Worldwide Increased ▲ **6.3%**

Excluding acquisitions/ divestitures on an operational basis | Worldwide Increased ▲ **6.2%***

Diluted Earnings Per Share

$1.96 | Increased ▲ **8.9%**

Adjusted Diluted Earnings Per Share*

$2.80 | Increased ▲ **8.1%**





"Our robust performance in the second quarter and first half of 2023 is a testament to the hard work and commitment of our colleagues around the world. We are entering the back half of the year from a position of strength with numerous catalysts, including becoming a two-sector company focused on Pharmaceutical and MedTech innovation."

Joaquin Duato
Chairman of the Board &
Chief Executive Officer
Johnson & Johnson

$13.7 Billion — Worldwide Pharmaceutical Sales

Pharmaceutical worldwide reported sales increased 3.1% or 3.8% operationally[1]. Primary operational drivers:

DARZALEX (daratumumab) injection for intravenous infusion 100 mg/5 mL, 400 mg/20 mL | Stelara (ustekinumab) | Erleada (apalutamide) 60 mg tablets | Tremfya (guselkumab) | CARVYKTI (ciltacabtagene autoleucel) | Spravato (esketamine) CII nasal spray | Uptravi (selexipag) tablets

$7.8 Billion — Worldwide MedTech Sales

MedTech worldwide reported sales increased 12.9% or 14.7% operationally[1]. Primary operational drivers:

Abiomed | Electrophysiology | Wound Closure | Biosurgery | Contact Lenses | Trauma | Surgical Vision | Endocutters | Knees | Hips | Energy

$4.0 Billion — Worldwide Consumer Health Sales

Consumer Health worldwide reported sales increased 5.4% or 7.7% operationally[1]. Primary operational drivers:

Neutrogena | Motrin IB | TYLENOL | nicorette | Stayfree | SUDAFED | Imodium

Note: values may have been rounded.

For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson's earnings release issued on July 20, 2023, available at http://www.investor.jnj.com/sales-earnings.cfm.

*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

[1]Non-GAAP measure; excludes the impact of translational currency.

Caution Concerning Forward-Looking Statements: This document contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the "Note to Investors Concerning Forward-Looking Statements" included in the Johnson & Johnson earnings release issued on July 20, 2023, as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.